Frankfurt - Delayed Quote EUR

Collegium Pharmaceutical, Inc. (354.F)

25.00
-0.80
(-3.10%)
At close: May 23 at 3:57:39 PM GMT+2
Loading Chart for 354.F
  • Previous Close 25.80
  • Open 25.20
  • Bid 25.20 x 70000
  • Ask 25.80 x 70000
  • Day's Range 25.00 - 25.20
  • 52 Week Range 22.00 - 38.60
  • Volume 279
  • Avg. Volume 4
  • Market Cap (intraday) 822.3M
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) 23.15
  • EPS (TTM) 1.08
  • Earnings Date Aug 6, 2025 - Aug 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

www.collegiumpharma.com

357

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 354.F

View More

Performance Overview: 354.F

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

354.F
9.42%
S&P 500 (^GSPC)
1.34%

1-Year Return

354.F
20.89%
S&P 500 (^GSPC)
10.16%

3-Year Return

354.F
64.47%
S&P 500 (^GSPC)
46.03%

5-Year Return

354.F
22.55%
S&P 500 (^GSPC)
96.34%

Compare To: 354.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 354.F

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    822.30M

  • Enterprise Value

    1.40B

  • Trailing P/E

    23.12

  • Forward P/E

    4.12

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.62

  • Price/Book (mrq)

    3.87

  • Enterprise Value/Revenue

    2.37

  • Enterprise Value/EBITDA

    4.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.61%

  • Return on Assets (ttm)

    7.95%

  • Return on Equity (ttm)

    19.23%

  • Revenue (ttm)

    664.28M

  • Net Income Avi to Common (ttm)

    43.89M

  • Diluted EPS (ttm)

    1.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    197.77M

  • Total Debt/Equity (mrq)

    411.94%

  • Levered Free Cash Flow (ttm)

    341.32M

Research Analysis: 354.F

View More

Company Insights: 354.F

Research Reports: 354.F

View More
Waiting for permission
Allow microphone access to enable voice search

Try again.